VRDN
Viridian Therapeutics, Inc.
$19.27
+0.01
(+0.05%)
Mkt Cap
1.73B
Volume
1,515,453
52W Range
13.18-34.29
Sector
Healthcare
Beta
0.90
EPS (TTM)
-3.48
P/E Ratio
-9.37
Revenue (TTM)
70.92M
Rev Growth (5Y)
+132.2%
EPS Growth (5Y)
N/A
Company Description
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.85M | 302,000 | 314,000 | 1.77M | 2.96M | 1.05M | 4.46M | 8.39M | 4.00M | 3.34M | 2.54M | 4.32M |
| Net Income | (342.60M) | (269.95M) | (237.73M) | (129.87M) | (79.41M) | (110.72M) | (41.87M) | (32.70M) | (26.51M) | (12.67M) | (11.33M) | (7.89M) |
| EPS | -3.32 | -3.98 | -5.31 | -3.91 | -6.66 | -31.20 | -20.31 | -16.57 | -20.66 | -17.57 | -21.00 | -52.46 |
| Free Cash Flow | (276.89M) | (232.83M) | (185.07M) | (94.64M) | (54.92M) | (29.82M) | (36.14M) | (27.29M) | (28.41M) | (7.23M) | (7.02M) | (2.48M) |
| FCF / Share | -3.27 | -3.43 | -4.14 | -2.95 | -4.61 | -8.38 | -17.30 | -13.83 | -22.15 | -10.03 | -13.02 | -16.48 |
| Operating CF | (276.39M) | (232.32M) | (184.17M) | (93.84M) | (54.58M) | (29.78M) | (36.06M) | (26.84M) | (28.17M) | (7.23M) | (6.90M) | (2.21M) |
| Total Assets | 899.42M | 742.40M | 490.42M | 435.09M | 203.71M | 131.25M | 30.26M | 66.15M | 52.48M | 4.26M | 12.90M | 8.09M |
| Total Debt | 50.69M | 21.09M | 21.05M | 5.26M | 1.04M | 455,000 | 8.30M | 10.30M | 9.92M | 1.04M | 1.10M | 80,000 |
| Cash & Equiv | 212.38M | 99.59M | 102.83M | 155.58M | 42.30M | 45.90M | 24.85M | 32.61M | 47.44M | 3.34M | 10.83M | 5.12M |
| Book Value | 722.17M | 671.64M | 442.02M | 395.06M | 187.72M | 120.04M | 15.75M | 51.34M | 38.51M | (326,000) | 10.41M | 5.99M |
| Return on Equity | -0.47 | -0.40 | -0.54 | -0.33 | -0.42 | -0.92 | -2.66 | -0.64 | -0.69 | N/A | -1.09 | -1.32 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 141,000 | 132,000 | 70.57M | 75,000 | 72,000 | 72,000 | 86,000 | 72,000 | 72,000 | 72,000 | 72,000 | 72,000 |
| Net Income | (104.90M) | (120.36M) | (34.60M) | (100.73M) | (86.91M) | (79.72M) | (76.69M) | (64.99M) | (48.54M) | (66.86M) | (47.66M) | (55.06M) |
| EPS | -1.03 | -1.11 | -0.34 | -1.00 | -0.87 | -0.81 | -1.15 | -1.02 | -0.79 | -1.35 | -1.09 | -1.27 |
| Free Cash Flow | (119.68M) | (23.99M) | (84.74M) | (75.42M) | (92.74M) | (73.45M) | (68.00M) | (46.16M) | (45.22M) | (38.05M) | (39.39M) | (45.55M) |
| FCF / Share | -1.17 | -0.28 | -1.04 | -0.92 | -1.14 | -0.92 | -1.02 | -0.72 | -0.74 | -0.77 | -0.90 | -1.05 |
| Operating CF | (119.65M) | (23.75M) | (84.61M) | (75.37M) | (92.65M) | (73.33M) | (67.71M) | (46.06M) | (45.22M) | (38.00M) | (38.98M) | (45.21M) |
| Total Assets | 789.02M | 899.42M | 577.14M | 582.32M | 660.98M | 742.40M | 771.90M | 585.66M | 630.38M | 490.42M | 328.76M | 351.47M |
| Total Debt | 51.17M | 50.69M | 23.82M | 21.34M | 21.22M | 21.09M | 21.11M | 20.96M | 21.06M | 21.05M | 20.82M | 5.51M |
| Cash & Equiv | 176.35M | 212.38M | 169.65M | 117.32M | 116.22M | 99.59M | 200.32M | 107.67M | 91.64M | 102.83M | 111.60M | 87.08M |
| Book Value | 636.01M | 722.17M | 502.97M | 515.17M | 604.47M | 671.64M | 707.50M | 529.34M | 582.53M | 442.02M | 283.58M | 315.86M |
| Return on Equity | -0.16 | -0.17 | -0.07 | -0.20 | -0.14 | -0.12 | -0.11 | -0.12 | -0.08 | -0.15 | -0.17 | -0.17 |
VRDN News
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Viridian Metals Commences 2026 Diamond Drill Program at the Kraken
Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program
Viridian Therapeutics to Participate in Upcoming June Investor Conferences